ClinicalTrials.gg
CompletedNCT01648153T2DMUpdated Nov 21, 2016

Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM

A Phase 2 interventional study of GSK1070806 and Placebo (saline) in Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed at 14 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-21.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies in Diabetes Mellitus by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · GlaxoSmithKline.

Enrollment
24th of 33
37 · median 78
Started
2012
with 2 others
Phase 2
9 of 38
none open now
Registered
29th of 38
by date

Among the 38 studies in Diabetes Mellitus by GlaxoSmithKline, this one is the 24th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2012, is one of 9 in phase 2, and was the 29th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 38 studies in Diabetes Mellitus by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies in Diabetes Mellitus by GlaxoSmithKline as a file.
02

Study summary

GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). The aims of this placebo controlled study are to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1070806 in obese subjects with Type 2 diabetes mellitus (T2DM), and to gain a better understanding of the mechanism by which GSK1070806 exerts its therapeutic effects.

Read the detailed description

The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C>7% but \<9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.

Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Efficacy
  • Obese
  • T2DM
  • IL-18
  • Monoclonal antibody (mAb)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of T2DM as determined by a responsible physician based on a medical evaluation including medical history, physical examination, and laboratory tests, with onset at least 6 months prior to Screening.
  2. Male or female between 18 and 70 years of age inclusive, at the time of signing the .
  3. levels ≥ 7.0 % and ≤ 9.5%; at Screening.
  4. On a stable dose of monotherapy with metformin for three months prior to screening, and at a total daily dose greater than or equal to 1000 mg for at least 2 months prior to dosing.
  5. Fasting plasma glucose level \< 13.3 mmol/L (240 mg/dL) at screening.
  6. Obese with ≥ 30 kg/m2, and \< 40 kg/m2.
  7. Presence of microalbuminuria: 30-300mg/L albumin in urine or Albumin Creatinine Ratio (ACR) ≥ 3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤ 30 mg/mmol (female and male)..
  8. The subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  9. A female subject is eligible to participate if she is of:

    • Non-
    • Child-bearing potential and agrees to use an acceptable form of .
  10. Male subjects must agree to use one of the contraception methods listed
  11. \< 2xULN; alkaline phosphatase and ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  12. Single or Average , QTcB or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block.

Exclusion criteria

Exclusion Criteria:

  1. Current evidence, or history within the last 7 days, of an influenza-like illness as defined by fever (>38°C) and two or more of the following symptoms: cough, sore throat, runny nose, sneezing, limb / joint pain, headache, vomiting / diarrhoea in the absence of a known cause, other than influenza.
  2. Use of anti-inflammatory drugs including , chronic maintenance therapy with NSAIDs, anti-Tumor Necrosis Factor (anti-TNF) or anti-Interleukin-1 (anti-IL1) within 60 days prior to dosing.
  3. Current evidence of ongoing or acute infection, history of repeated, chronic or opportunistic infections (e.g. recurrent folliculitis, other cutaneous infections or repeated pneumonia) or history of a serious bacterial infection within 6 months of randomisation.
  4. History of or significant cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions.
  5. History chronic granulomatous infections, such as of Mycobacterium tuberculosis or any other previous Mycobacterium infection.
  6. less than 60ml/min
  7. Screens positive of surface antigen, antibody or (HIV)
  8. History of a severe allergic reaction, anaphylaxis or immunodeficiency.
  9. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  10. A positive pre-study drug/alcohol screen.
  11. History of regular alcohol consumption within 6 months of the study
  12. The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  13. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  14. Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
  15. History of sensitivity to any of the study medications, or components thereof
  16. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  17. Pregnant females as determined by positive serum or urine hCG test at screening.
  18. Lactating females.
  19. Unwillingness or inability to follow the procedures outlined in the protocol.
  20. Subject is mentally or legally incapacitated.
  21. Subject has received a (s) within 30 days of randomisation or will require vaccination with a live attenuated vaccine prior to the end of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    GSK1070806 0.25mg/kg

    TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart

    Biological: GSK1070806

  • Active comparator
    GSK1070806 5mg/kg

    Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart

    Biological: GSK1070806

  • Placebo comparator
    Placebo (Saline)

    Two IV administrations of saline 4 weeks apart

    Other: Placebo (saline)

Interventions

  • BiologicalGSK1070806

    To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration

  • OtherPlacebo (saline)

    To compare the efficacy and biomarker changes between placebo and active groups

  • BiologicalGSK1070806

    To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration

06

What researchers measure

Primary outcomes

  1. Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT)

    To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM

    Time frame: Up to 85 days after the first does

Secondary outcomes

  1. Safety and tolerability parameters include: adverse events, clinical laboratory tests, electrocardiograms (ECGs), and vital signs

    To evaluate the safety and tolerability of two repeat intravenous dose administrations of GSK1070806 in obese subjects with T2DM

    Time frame: Up to 210 days after the first dose

  2. Change from baseline in % HbA1c, fasting blood insulin, and C-peptide levels; change from baseline in weighted mean insulin, and C-peptide levels [AUC (0-4hrs)] post-MMT and derived measures of insulin sensitive

    To evaluate the effect of two repeat intravenous dose administrations of GSK1070806 on additional markers of efficacy, in obese subjects with T2DM

    Time frame: Up to 85 days after the first dose

  3. AUC(0-τ)

    To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM

    Time frame: Up to 210 days after the first dose

  4. Serum levels of free IL-18 and drug bound IL 18

    To investigate the effect of repeat intravenous doses of GSK1070806 on free and drug bound IL 18 levels (if measurable) in obese subjects with T2DM.

    Time frame: Up to 210 days after the first dose

  5. Change from baseline in serum and/or plasma levels of biomarkers of inflammation (e.g. hs-CRP, and IL-6) and metabolic disease (e.g. adiponectin, fructosamine, total cholesterol, high-density lipoprotein (HDL)/low-density lipoprotein (LDL), triglycerides

    To explore the pharmacodynamic (PD) effect of repeat intravenous doses of GSK1070806 on biomarkers of inflammation and metabolic disease

    Time frame: Up to 85 days after the first dose

  6. Change from baseline in waist circumference and BMI

    To investigate the effect of repeat intravenous doses of GSK1070806 on body composition in obese subjects with T2DM

    Time frame: Up to 85 days after the first dose

  7. Cmax

    To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM

    Time frame: Up to 210 days after the first dose

  8. Tmax

    To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM

    Time frame: Up to 210 days after the first dose

  9. after the second dose λz

    To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM

    Time frame: Up to 210 days after the first dose

  10. t1/2

    To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM

    Time frame: Up to 210 days after the first dose

07

Study locations

14 sites
  • GSK Investigational Site
    Alicante, 03004, Spain
  • GSK Investigational Site
    Alzira/Valencia, 46600, Spain
  • GSK Investigational Site
    Granada, 18012, Spain
  • GSK Investigational Site
    La Roca del Valles (Barcelona), 08430, Spain
  • GSK Investigational Site
    Lleida, 25198, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Malaga, 29010, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    Petrer, Alicante, 03610, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Birmingham, Warwickshire B15 2TT, United Kingdom
  • GSK Investigational Site
    Cambridge, CB2 2GG, United Kingdom
  • GSK Investigational Site
    Dundee, DD1 9SY, United Kingdom
08

References and documents

Publications

  • McKie EA, Reid JL, Mistry PC, DeWall SL, Abberley L, Ambery PD, Gil-Extremera B. A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus. PLoS One. 2016 Mar 1;11(3):e0150018. doi: 10.1371/journal.pone.0150018. eCollection 2016. PubMed 26930607 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Sep 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2012
First posted
Jul 24, 2012
Start
Aug 2012
Primary completionActual
Sep 2013
CompletionActual
Jan 2014
Last update
Nov 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01648153
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 24, 2012
Start date
Aug 2012
Primary completion
Sep 2013
Completion
Jan 2014
Last update
Nov 21, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1070806

Start the discussion